23 reports

  • RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, PHASE II, 2017
  • RESPIRATORY DISORDERS THERAPEUTICS MARKET, GLOBAL, PIPELINE PRODUCTS, PRECLINICAL,

HUNDREDS OF PHARMACEUTICAL SPECIFIC NEWS SOURCES ARE MONITORED ON A DAILY BASIS.

  • Pharmaceutical
  • Respiratory Disease
  • Respiratory Treatment
  • Therapy
  • Galectin Therapeutics Inc.
  • Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 1)
  • 8.3.2 Deals by Stage of Development and Value

Of these, only one product - TaiwanJ Pharmaceuticals' JKB-## is in clinical development.

  • Digestive System Disorder
  • Pharmaceutical
  • Therapy
  • Catabasis Pharmaceuticals, Inc.
  • Galectin Therapeutics Inc.
  • Competitive Landscape
  • Of Contents

Dainippon Sumitomo Pharma.

  • Pharmaceutical
  • Therapy
  • Galectin Therapeutics Inc.
  • Galmed Pharmaceuticals Ltd.
  • Genfit SA
  • NASH - Phase II-III Pipeline, 2017
  • 9.2.1 Ocaliva (Obeticholic Acid)

INVENTIVA PHARMA (2017).

  • Digestive System Disorder
  • Health Care Provider
  • Pharmaceutical
  • Therapy
  • Galectin Therapeutics Inc.
  • NASH TARGET ANALYSIS BASED-ON MECHANISM
  • COMPANY- GALECTIN THERAPEUTICS

HEADQUARTERS COMPANY- INTERCEPT PHARMACEUTICALS OVERVIEW NEWYORK INTERCEPT PHARMACEUTICAL IS A BIOPHARMACEUTICAL COMPANY FOUNDED IN THE YEAR 2002 AND IS HEADQUARTERED IN NEW YORK, UNITED STATES.

  • Biomarker
  • Pharmaceutical
  • Therapy
  • Boehringer Ingelheim GmbH
  • Galectin Therapeutics Inc.
  • Renal Diseases, Global, Pipeline Products, 2017 (Part 3)
  • 8.3 Co-development Deals

Indeed, strategic consolidations provide a significant source of new drugs for the pharmaceutical industry.

  • Pharmaceutical
  • Renal Disease
  • World
  • Deals & Alliance
  • Galectin Therapeutics Inc.
  • Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details
  • Galectin Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details
  • Healthcare
  • Pharmaceutical
  • United States
  • Company
  • Galectin Therapeutics Inc.
  • DORMANT PRODUCTS, H1 2017
  • GMCT-01 - DRUG PROFILE

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Conatus Pharmaceuticals Inc
  • GMCT-01 - Drug Profile
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • CUMBERLAND PHARMACEUTICALS, INC.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2016
  • Hypertension
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Conatus Pharmaceuticals Inc
  • GMCT-01 - Drug Profile
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • DORMANT PROJECTS, H2 2016
  • DISCONTINUED PRODUCTS, H2 2016
  • Digestive System Disorder
  • Hospital
  • Pharmaceutical
  • Therapy
  • Galectin Therapeutics Inc.
  • GMCT-01 - DRUG PROFILE
  • Myocardial Fibrosis - Companies Involved in Therapeutics Development

Daewoong Pharma is headquartered in Seoul, South Korea.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • GMCT-01 - DRUG PROFILE
  • APR 25, 2017: GALECTIN THERAPEUTICS RECEIVES NOTICE OF JAPANESE DECISION TO GRANT A COMPOSITION OF MATTER PATENT FOR GR-MD-02

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • OF CONTENTS
  • cells.
  • Pharmaceutical
  • Therapy
  • United States
  • Corporate Finance
  • Galectin Therapeutics Inc.
  • GMCT-01 - DRUG PROFILE
  • GLYCOMIMETICS INC

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • Therapy
  • United States
  • Litigation And Patent
  • Galectin Therapeutics Inc.
  • GM-CT-01 - DRUG PROFILE
  • GALECTIN THERAPEUTICS, INC.

(PepTx) is a pharmaceutical company.

  • Hospital
  • Pharmaceutical
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES
  • LIVER FIBROSIS - DORMANT PROJECTS, H1 2017 (CONTD..1), H1 2017

Falk Pharma GmbH (Dr.

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.
  • LIVER FIBROSIS - DORMANT PROJECTS, H2 2017 (CONTD..1), H2 2017
  • GMCT-01 - DRUG PROFILE

Falk Pharma GmbH (Dr.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES
  • GMCT-01 - DRUG PROFILE

TRACON PHARMACEUTICALS, INC.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • BIORION TECHNOLOGIES BV
  • APR 25, 2017: GALECTIN THERAPEUTICS RECEIVES NOTICE OF JAPANESE DECISION TO GRANT A COMPOSITION OF MATTER PATENT FOR GR-MD-02

The company operates through its subsidiaries, namely, Horizon Pharma USA, Inc., Horizon Pharma (UK) Limited, Horizon Pharma AG and Horizon Pharma GmbH.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.
  • Galectin Therapeutics, Inc., Key Facts
  • lead drug DAVANAT, is co-administered with a chemotherapeutic agent to reduce toxicity of the chemotherapy.

Pro-Pharmaceuticals maintain the intellectual property rights to Davanat.

  • Pharmaceutical
  • United States
  • World
  • Product Initiative
  • Galectin Therapeutics Inc.
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H1 2015
  • Cardiac Fibrosis - Therapeutics under Development by Companies

The company was formerly known as Pro-Pharmaceuticals, Inc.

  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • Galectin Therapeutics Inc.